Yes, you can test positive for anti-CCP and have no symptoms at all. Antibodies linked to RA can show up in the blood years before any joint swells: in one Dutch study of stored blood donations, anti-CCP or rheumatoid factor appeared a median of 4.5 years early, and in some cases more than a decade early. A positive result raises the chance of rheumatoid arthritis (RA), but it isn’t a diagnosis, and many people who test positive never develop it.
Here’s what the test measures, how RA seems to begin, what the best studies say about the odds, and where the prevention trials stand in 2026. Please don’t start, stop or change any medication because of anything here without talking to your doctor first.
Prefer to watch? This article goes with our video, Positive Anti-CCP, No Joint Pain Yet? What the Test Means (11 min).
Can you test positive for anti-CCP and have no symptoms?
Yes. Anti-CCP is short for anti-cyclic citrullinated peptide antibodies. The lab uses a small, ring-shaped piece of protein as bait to catch a family of antibodies called ACPA (anti-citrullinated protein antibodies). Those antibodies target proteins that have been chemically altered in a normal process called citrullination, where an enzyme swaps one protein building block, arginine, for a slightly different one, citrulline.
The test is quite specific. In a 2007 analysis that pooled 37 studies, about 95% of people without RA tested negative, compared with 85% for the older rheumatoid factor (RF) test.1 But specific isn’t the same as certain. Researchers estimate that around 1% of the general population tests positive for anti-CCP.2 A positive result tells you that one part of the immune system has started reacting to citrullinated proteins. It doesn’t tell you that RA is coming, or when.
The test also misses people. In that same analysis, only 67% of people with RA had a positive anti-CCP.1 About a third of people with the disease test negative, and their RA may start differently.
How RA begins: the years before the first swollen joint
The clearest timeline comes from blood banks. Dutch researchers went back to frozen blood that 79 people had donated before they were ever diagnosed with RA. Nearly half of them (49%) already had anti-CCP or RF in their blood before their first symptom, a median of 4.5 years beforehand, with the longest gap close to 14 years.3 Among matched donors who never developed RA, only 0.6% of samples were anti-CCP positive. A Swedish study of 83 people found the same pattern, and anti-CCP was the strongest predictor of later RA of all the antibodies tested.4
Those years aren’t completely still. In a US study of stored blood samples from 81 people who later developed RA, the antibodies recognized more and more citrullinated targets as diagnosis got closer, and that spread went along with rising levels of inflammatory messengers such as TNF and interleukin-6.5 The process seems to build slowly rather than all at once.
Where that first mistake happens is still being worked out. One leading idea points to the body’s moist linings, like the lungs and gums. In a Swedish case-control study, people who had smoked and carried two copies of the HLA “shared epitope” genes had about 21 times the risk of anti-CCP-positive RA compared with non-smokers who carried none, and lung cells from smokers showed citrullinated proteins that non-smokers’ didn’t.6 A gum bacterium, Porphyromonas gingivalis, makes its own citrullinating enzyme, a finding so far from lab studies.7 Both are serious leads. Neither is proven as a cause.
What are the odds that a positive anti-CCP turns into RA?
The best numbers come from one long-running project in Leeds, in the UK. Since 2007, its researchers have tested people with new, vague joint or muscle aches but no swollen joints, mostly referred by their family doctor, and then followed everyone who was anti-CCP positive.
In 100 consecutive anti-CCP-positive people they followed, half (50) developed inflammatory arthritis, most of it RA, after a median of 7.9 months.8 The researchers found four things that sorted people by risk: tender joints in the hands or feet, morning stiffness lasting 30 minutes or more, high antibody levels, and inflammation visible on an ultrasound scan of the joints. None of the 5 people with none of these progressed, compared with 31% of those at moderate risk and 62% of those at high risk.
A larger update covered 6,780 people recruited from family practices across the UK between 2007 and 2019.9 About 3% tested positive, and 45% of those went on to develop inflammatory arthritis. A high antibody level was the strongest single warning sign, with about 9 times the odds of progressing. Pain in the hands or feet added to the risk. And there was a reassuring group: among people with a low-positive result and no pain in their hands or feet, 96% did not progress.
One more Leeds finding helps answer a question people ask on forums: can it go away? Among 90 anti-CCP-positive people whose ultrasound showed hidden joint inflammation, that inflammation had cleared by 12 months in 43 of them (48%).10 It was more likely to clear with a low antibody level, only one affected joint and a low ESR (a basic blood marker of inflammation), and possibly with a negative RF. That study tracked joint inflammation, not the antibody itself, but it shows the process doesn’t always move forward.
What raises or lowers the risk
These are the factors that keep coming up across the studies above. None of them predicts the future for one person, but they explain why two people with the same positive result can get very different advice.
| Factor | What studies found | What to ask about |
|---|---|---|
| How high the antibody is | High levels carried about 9 times the odds of progressing in the large Leeds cohort.9 | The exact number, and how many times above the lab’s cut-off it is |
| Rheumatoid factor | A negative RF was a weaker, less certain sign that hidden inflammation would settle.10 The largest prevention trial enrolled people positive for both antibodies because they’re at higher risk.11 | Whether RF was tested, and the result |
| Where it hurts | Pain in the hands or feet raised the risk; low-positive people without it rarely progressed.9 | Which joints to watch, and what counts as a reason to call |
| Morning stiffness | Stiffness of 30 minutes or more was one of the four warning signs in Leeds.8 | Whether to keep a simple daily record of stiffness |
| Inflammation on a scan | Ultrasound signs of inflammation predicted progression,8 though about half cleared within a year.10 | Whether an ultrasound would change anything in your case |
| Smoking | The best-established environmental risk factor for anti-CCP-positive RA, especially in people with certain HLA genes.6 | Support to stop, if it applies to you |
Can RA be prevented if you’re anti-CCP positive?
Not yet, as far as anyone has shown. As of 2026, no medicine is approved to prevent RA in people who test positive,12 and the trials so far are a mixed picture.
- Hydroxychloroquine (StopRA). This US trial gave 144 people with anti-CCP at least twice the upper limit of normal either hydroxychloroquine or placebo for a year. By 36 months, RA had developed in 30.4% of the drug group and 32.9% of the placebo group, which is no real difference.12
- Abatacept, 12 months (APIPPRA). In 213 people with both anti-CCP and RF plus joint pain, 6% developed arthritis during treatment, against 29% on placebo.11 After the drug stopped, the gap narrowed: 25% against 37% at two years. Longer follow-up of 143 participants, published in January 2026, found the delay was still measurable at four years, but smaller, and people with a broad mix of autoantibodies benefited most.13
- Abatacept, 6 months (ARIAA). In 100 anti-CCP-positive people with joint pain and inflammation on MRI, 35% of the abatacept group had developed RA by 18 months, compared with 57% on placebo.14
Our reading: these trials show RA can be delayed in people at very high risk, which is real progress. They haven’t shown it can be stopped for good, and every trial enrolled people who already had joint pain or high antibody levels. None of them tells us what to do for someone with a positive test and no symptoms.
Why we care about this one
Annesse, Kristin’s mom and the other half of the “we” on this site, didn’t have RA. She had the opposite problem from the one in this article. Her illness started in the summer of 1992, and for years her lab results didn’t always match how she felt, until doctors finally confirmed lupus, chronic fatigue syndrome and fibromyalgia. Kristin was a teenager and watched it happen.
A positive test with no symptoms and symptoms with no positive test leave you in the same spot: waiting, and not sure what you’re waiting for. If we were in that spot now, we’d want the plan written down before leaving the office: what the number was, when to recheck, and exactly which changes should make us call.
Questions to bring to your doctor
- Was my anti-CCP low-positive or high-positive, and was rheumatoid factor tested too?
- Since I don’t have symptoms, what would you want me to watch for, and how soon should I call if it happens?
- Would a referral to a rheumatologist, or an ultrasound of my hands and feet, change anything for me right now?
- Are there research studies for people who test positive that I could ask about?
What we still don’t know
Nobody can yet tell an individual person with a positive anti-CCP and no symptoms whether, or when, they’ll develop RA. Most of the risk numbers come from people who already had aches, so the risk for someone with none is less well measured. The lungs-and-gums idea is a well-supported hypothesis, not a proven cause. And the prevention trials so far have delayed RA in high-risk groups without showing a lasting effect once treatment stops, so whether treating anyone this early is worth the side effects and cost is still an open question.
A positive result is a reason to have a plan and a doctor who knows about it. On its own, it isn’t a diagnosis.
Quick answers
Does a positive anti-CCP mean I have rheumatoid arthritis?
No. RA is diagnosed from swollen joints plus test results, not from an antibody alone. A positive anti-CCP means a higher chance of RA, and many people who test positive never develop it.
How long after a positive anti-CCP does RA develop?
It varies widely. In stored blood samples, anti-CCP or rheumatoid factor appeared a median of 4.5 years before symptoms. In people who already had joint aches when tested, about half developed arthritis, most within the first year or two.
What if I’m anti-CCP positive but rheumatoid factor negative?
Anti-CCP is the more specific test for RA, and a negative RF is generally the more reassuring partner result, but it doesn’t cancel the anti-CCP.
Can anti-CCP antibodies go away?
There’s little good data on the antibody itself disappearing. What we do know is that the process doesn’t always move forward: in one UK study, hidden joint inflammation seen on ultrasound cleared within a year in about half of anti-CCP-positive people.
Can a positive anti-CCP be a false positive?
It can. About 5% of people without RA tested positive in pooled studies, and low-positive results carry less risk than high ones. A repeat test and a rheumatologist’s view help sort it out.
Sources
- Nishimura K, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808. doi.org/10.7326/0003-4819-146-11-200706050-00008
- Nam JL, et al. Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms, a cohort study. Ann Rheum Dis. 2016;75(8):1452-1456. doi.org/10.1136/annrheumdis-2015-207871
- Nielen MMJ, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380-386. doi.org/10.1002/art.20018
- Rantapää-Dahlqvist S, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741-2749. doi.org/10.1002/art.11223
- Sokolove J, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012;7(5):e35296. doi.org/10.1371/journal.pone.0035296
- Klareskog L, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38-46. doi.org/10.1002/art.21575
- Wegner N, et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2662-2672. doi.org/10.1002/art.27552
- Rakieh C, et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis. 2015;74(9):1659-1666. doi.org/10.1136/annrheumdis-2014-205227
- Garcia-Montoya L, et al. Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational study. Arthritis Res Ther. 2022;24(1):26. doi.org/10.1186/s13075-022-02717-w
- Garcia-Montoya L, et al. Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study. Lancet Rheumatol. 2024;6(2):e72-e80. doi.org/10.1016/S2665-9913(23)00305-3
- Cope AP, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403(10429):838-849. doi.org/10.1016/S0140-6736(23)02649-1
- Deane KD, et al. A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis. Arthritis Rheumatol. 2026;78(4):809-820. doi.org/10.1002/art.43366
- Cope AP, et al. Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2026;8(3):e171-e180. doi.org/10.1016/S2665-9913(25)00371-6
- Rech J, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403(10429):850-859. doi.org/10.1016/S0140-6736(23)02650-8
How we made this article. We start from the research behind our video, draft with help from AI writing tools, and check every number and claim against the original papers listed above. Last fact-check: October 15, 2026. Spot an error? Tell us on any of our channels and we’ll fix it.
This article is education, not medical advice. It doesn’t diagnose or treat any condition. Talk to your doctor before changing your care, and never stop or change a medication on your own.
